SST and type 2 diabetes mellitus: While the pathophysiology of defective glucagon counterregulation during treatment-induced hypoglycemia in T1D and advanced T2D remains unclear, mounting evidence suggests that the hypersecretion of inhibitory paracrine hormone, SST, may suppress counterregulatory glucagon secretion via SSTR2 expressed by α-cells.